Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

Jiaojiao Hao,Wenhua Fan,Yizhuo Li,Ranran Tang,Chunfang Tian,Qian Yang,Tianhua Zhu,Chaoliang Diao,Sheng Hu,Manyu Chen,Ping Guo,Qian Long,Changlin Zhang,Ge Qin,Wendan Yu,Miao Chen,Liren Li,Lijun Qin,Jingshu Wang,Xiuping Zhang,Yandong Ren,Penghui Zhou,Lijuan Zou,Kui Jiang,Wei Guo,Wuguo Deng

Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

2019

Background As the selective inhibitor of BRAF kinase, vemurafenib exhibits effective antitumor activities in patients with V600 BRAF mutant melanomas. However, acquired drug resistance invariably develops after its initial treatment.

Keywords:

Melanoma
Cancer research
Drug resistance
Melatonin
Vemurafenib
Biology
Telomerase reverse transcriptase
Cancer stem cell
Mutant
Kinase
NF-κB
Apoptosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations